Recent Finacing
Recent Raise
Oxagen, a Milton Park, UK–based drug discovery and development company focused on inflammation, develops CRTH2 antagonists including OC000459 (in Phase IIb for moderate persistent asthma) and backup compounds.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors